Bright Minds Biosciences' Investigational New Drug Application For Developmental And Epileptic Encephalopathies And Related Protocol BMB-101-105 Has Been Placed On Partial Clinical Hold Following FDA Review

Loading news article.

Bright Minds Biosciences' Investigational New Drug Application For Developmental And Epileptic Encephalopathies And Related Protocol BMB-101-105 Has Been Placed On Partial Clinical Hold Following FDA Review | WAPE

Bright Minds Biosciences' Investigational New Drug Application For Developmental And Epileptic Encephalopathies And Related Protocol BMB-101-105 Has Been Placed On Partial Clinical Hold Following FDA Review

Article summary

Related companies

Analyzed by WAPE AI.

Comments —